Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-based chemoradiotherapy regimens for newly diagnosed glioblastoma
2008-001144-39Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Avastin + irinotecan + cerebral radiotherapy with Avastin + Temodal + cerebral radiotherapy (2 arms). Primary endpoint: Response rate. Started Apr 2008; status: completed.
02
Drugs
bevacizumabtemozolomideirinotecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-001144-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001144-39.